REFERENCES:

1. *International Conference on Harmonization,* Step 4 Version dated 25 October 2006, Impurities in New Drug Substances Q3A (R2).
2. *International Conference on Harmonization,* Step 4 Version dated 10 November 2000, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7.
3. Stanley H.Nusim,(2009), Active Pharmaceutical Ingredients Development, manufacturing and regulation; *Drugs and The Pharmaceutical Sciences,* (190-191).
4. General Information/ (1086) Impurity in official article USP 26.
5. *International Conferences on Harmonization*, Q3A Federal Register, 2000; Draft Revised Guidance on Impurities in new drug Substances. **65, (140)**: 45085-45090.
6. *International Conferences on Harmonization*, (2000), Draft Revised Guidance on impurities in new drug products.Q3B Federal Register: **65(139):** 44791- 44797.
7. *International Conferences on Harmonization*,(1997), impurities Guidelines for residual solvent. Q3C Federal Register: **62(247)**: 673-677.
8. ICH topic Q3A(1995) Impurities testing Guideline, Impurities in new drug substances, The European Agency for the Evaluation of Medicinal products, Human medicines evaluation unit.
9. *International Conferences on Harmonization Specifications.* (1999)Q6A: Test procedures and Acceptance Criteria for New drug substances and new drug products. Chemical substances **65(146):** 67488.
10. Lohr L L, Sharp TR, Alsante KM and Hatajik TD (2001), Isolation and Identification of process related impurities and degradation products form pharmaceutical drug candidates. Part II: The role of NMR and Mass Spectroscopy. *American pharmaceutical review.* **4** (**1**): 70-78.
11. Gorog,S,(2003), Chemical and analytical characterization of related organic impurities in drugs. *Anal. Bioanal. chem*., **377:** 852-862.
12. Ahuja S (1998) *Impurities Evaluation of pharmaceuticals.* Marcel Dekker, New York, 1-142.
13. Gorog S (2000) *Identification and Determination of impurities in drugs*. Elsevier science publishing Company, Amsterdam, 1- 154.
14. Riley T N (1998) Steric aspects of drug action. *Pharmacist* , **23** (**3**):40-51.

15. *International Conference on Harmonization* (1997) Impurities, Q3C-Guidelines for Residual solvents, Q3C. Federal Register **62**(**247**): 67377.
16. Jacobs P, Dewe W, Flament A, Gibella M, Ceccato A(2005) A new validation approach applied to the GC determination of impurities in organic solvents, *J pharm Biomed anal* **40**: 294-299.
17. Gimeno P, Besacier F, Bottex M, Dujourdy I, Chaudron-Thozet H,(2005), A study of impurities in intermediates and 3,4 methylenedioxymethanmphetamine(MDMA) samples produced via reductive amination routes, *Forensic science international* **155**: 141- 144.
18. Buhler V(1998) Vademecum for vitamine formulation. Struttgart, Germany, *Wiss, Verl-Ges*, **142**: 36.
19. Hoq M M, Morsheda S B and Gomes D J,(1991), Development of appropriate preservative system for liquid antacid: bacterial contaminants in antacid sample *J Microbio* **8(1)**: 5.
20. Fras I, Cassagnau P and Michel A (1998) Influence of processing conditions on the leaching of thermal stabilizers from plasticized poly (vinyl chloride) in the presence of water. *J appl polym sci* **70:** 2391-2394.
21. Roy J, Islam M, Khan A H, Das S C, Akhteruzzaman M, Deb A K,Alam A H, (2001) diclofenac sodium injection sterilized by autoclave and the occurrence of cyclic reaction producing a small amount of impurity. *J Pharma sci,* **90**: 41-544.
22. Roy J, Mahmud M, Sobhan A, Aktheruzzaman M, Al- Faooque M and Ali E (1994), Marketed vitamin B- complex injectables: stability and mutual interaction, *Drug Dev .And Ind Pharm* **20**(**13**): 2157-2163.
23. Hoerle S L, Evans K D, and Snider B G,(1992) *HPLC Determination of impurities in a 3rd Generation Cephalosporin:* eastern analytical symposium,**12**: 1-12 .
24. Sanga S V,(1979) Review of glass types available for packaging parenteral solution, *J parenteral Drug Assn* **33**: 61-64.
25. Isaacs, J T,(1993), 5 Alpha- reductase Inhibitors and treatment of benign prostatic hyperplasia, *Drugs Today* **29**: 335-342.
26. Komati Satyanarayana, Katkam Srinivas, Vurimidi Himabindu, Ghanta Mahesh Reddy, (2007), *Organic process research and Development*, **11:** 842-845.

27. Skoog, D A,(1985), Principle of instrumental Analysis, third edition, Saunder college publishing, Philadelphia,4, Still, W. C: Kahn,M: Mitra, A.(1978), *Journal of organic Chemistry* , **43:** 2923-2924.
28. Knox, J H, Pyper, H M, (1986) *journal of Chromatography*, **363**: 1-30.
29. Joachim E (1998) The use of hyphenated LC-MS technique for characterization of impurity profiles during drug development: *J Pharm Biomed Anal.* **18**:707-709.
30. Nisha M, Ismail M, Duncan F, Maili L, Jeremy K N, and John C L, (1999) Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR based diffusion measurement, *J Pharm Biomed Anal* **19**: 511-514.